Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Understanding these potential contributors helps clinicians provide appropriate patient education and management strategies
In December of 2017, the U.S Food and Drug Administration (FDA) approved Novo Nordisks semaglutide (brand name Ozempic) for the treatment of type-2 diabetes
Greenberger, University of Pittsburgh Medical Center-Shadyside, USA Copyright 2014 Aquilano, Baldelli and Ciriolo
In a cross-sectional survey asking 524 patients with diabetes and caregivers about motivational factors and adherence methods used, medication education was identified as a key factor
Semaglutide was present in the milk of lactating rats, however, due to species-specific differences in lactation physiology, the clinical relevance of these data are not clear (see Data)
This phenomenon does not necessarily indicate loss of medication potency but rather reflects complex physiological adaptations
